GENE ONLINE|News &
Opinion
Blog

2022-01-20| Asia-PacificFunding

APAC CRO Novotech Mulls IPO after $255 Million Round

by Joy Lin
Share To

Asia-Pacific contract research organization (CRO) Novotech Health Holdings is mulling an IPO in the US or Hong Kong after it raised $255 million in a financing round that valued the firm at $3 billion, reported Bloomberg Wednesday. 

Novotech’s new plans come after the firm cancelled a planned September IPO that would have seen it raise $700 million on the Hong Kong stock exchange, due to volatile market conditions. 

Novotech Holdings operates integrated labs and Phase 1 facilities and provides services for drug and clinical development. It was formed from a 2020 merger between Novotech in Singapore and Australia and PPC in mainland China. 

In addition to its $255 million financing round, Novotech also confirmed a $505 million debt refinancing. The fundraising brought in multiple new investors and saw participation from all existing shareholders. Novotech added that TPG, a private equity firm, remains its controlling stockholder. 

TPG went public on the Nasdaq last week, raising over $1 billion. The public float valued the company at over $9.5 billion. 

Related Article: GeneOnline’s Top 10 Hong Kong Biotech IPOs of 2021

Novotech to Use Proceeds for Expansion and Growth

Proceeds from the fundraising will help Novotech pursue M&As, expand into other regions and boost data, AI and tech-related offerings. 

“We are grateful for the support and recognition we received from multiple global investors that participated in the private placement transaction,” said Novotech CEO John Moller. “In addition, we are very pleased to receive continued endorsement from our existing investors. We look forward to accelerating our growth by pursuing various strategic M&A and tech enablement initiatives and seek to better serve our biotech and pharmaceutical clients and support the clinical research industry in the development of a wide spectrum of therapeutic areas.”

Related Article: Are Decentralized Clinical Trials Taking Root in Japan?

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Major U.S. Organization BIO Severs Ties With Member WuXi AppTec Amid U.S. Government’s Security Concerns
2024-03-15
AbbVie Boosts Global Manufacturing with $223 Million Expansion in Singapore
2024-01-29
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top